Businesses face new rules under Delaware's new privacy laws. Here's how it protects your data
The groundbreaking law gives residents more control over how businesses handle their personal information, positioning Delaware as a regional leader in data privacy and consumer rights. It also requires companies to provide simple and accessible privacy notices to help consumers understand how their data is collected, used and protected.
Passed in 2023, the Delaware Personal Data Privacy Act requires businesses to obtain explicit consent before collecting or sharing personal information. Data including names, addresses, phone numbers, emails and precise location data are covered under the law.
The state's Department of Justice, through its Fraud & Consumer Protection Division, will oversee the enforcement of the new regulations. Attorney General Kathy Jennings stated that the law gives her office essential tools to protect consumers' data privacy and security.
The new privacy law gives Delaware residents several rights:
Opt-in for sensitive data: Businesses must obtain explicit consent before using or sharing sensitive personal information, including race, religion and health conditions.
Opt-out of data sales and targeted advertising: Consumers can decline the sale of their data, automated decision-making, and personalized ads.
Access, correction and deletion rights: Residents can request access to their data, correct inaccuracies, or delete their information.
Anti-discrimination protection: Businesses cannot unlawfully use personal data to discriminate against consumers.
DIGITAL ACCESS UPGRADE: Delaware secures $17.4M to connect entire state to high-speed internet
The law provides even stricter safeguards for children's privacy:
For children under 13, businesses must secure parental consent before collecting any personal data.
For teens ages 13 through 17, companies must obtain direct consent before selling their information or using it for targeted advertising.
Delaware residents who want to learn more about the state's new privacy rights or file complaints about potential violations can visit privacy.delaware.gov.
You can contact Anitra Johnson at ajohnson@delawareonline.com.
This article originally appeared on Delaware News Journal: Delaware's Personal Data Privacy Act addresses data collection
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Ticket fraud warning issued by bank as ‘Gen-Z adults most likely to be targeted'
People falling for ticket scams are losing £150 on average – with Gen-Z adults particularly likely to be targeted, a bank is warning. Barclays said that August can be one of the strongest months of the year for reports of purchase scams. One in six (17%) Gen-Z adults aged 18 to 27 said they had been caught out or coerced into paying for tickets that did not exist, slightly higher than Millennials (aged 28-43), at 16%, according to the Barclays Scams Bulletin. Gen-Z adults are also the most likely to know someone who has either fallen victim to or been targeted by a scam, at 23% compared with 19% for Millennials and 14% across all age groups across the UK. The bank's own scam claims data indicates that the peak months for purchase scams last year were April, closely followed by August. As fans seek out tickets for upcoming events, often through resellers, more than two-fifths (42%) of people surveyed said they feel more worried about falling victim to a scam than they did 12 months ago. Tickets scams often originate on social media, the bank said. Kirsty Adams, fraud and scams expert at Barclays, said scammers are 'ready to cash in on the hype' around concerts such as the Oasis tour. She said: 'Whether it's a once-in-a-lifetime concert or a sold-out summer sporting event, the rush to grab tickets can cloud judgment, which is why we're urging fans to pause for thought before they part with their money to avoid falling victim to opportunistic summer scammers. 'Social media platforms and online marketplaces provide a hotbed for these scams to take place.' Opinium surveyed 2,000 people in June and Barclays also used some of its own data on scams for the research. Here are Ms Adams's 'safe' tips for buying tickets: S – Stop and research Do your due diligence. Take a moment to check the website, read reviews, and confirm if tickets can be transferred or resold. Just a couple of minutes of research can prevent days of regret. A – Ask someone you trust Get a second opinion before buying. Speak to a friend or family member who might know the seller or website and see if it sounds legitimate to them. F – Flag unrealistic deals Be wary of unlikely offers. If the price seems too good to be true, it probably is. Question why the seller is offering such a discount and whether they are asking for unusual payment methods. E – Ensure secure payment Always use a credit card or another secure payment method. This gives you added protection if something goes wrong with your purchase. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Associated Press
2 days ago
- Associated Press
Biohaven Ltd. Class Action: Levi & Korsinsky Reminds Biohaven Ltd. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 12, 2025
NEW YORK - July 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. (NYSE: BHVN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team: BHVN investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S NEXT? If you suffered a loss in Biohaven Ltd. during the relevant time frame, you have until September 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against Biohaven Ltd.. Listen now and find out if you are eligible to join the lawsuit. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171
Yahoo
2 days ago
- Yahoo
UnitedHealth Group Stock Sinks as Company Confirms DOJ Investigations
UnitedHealth Group (UNH) on Thursday confirmed several reports in recent months that the Department of Justice is probing aspects of its business, sending shares lower in recent trading. The company said it has "proactively reached out to the Department of Justice after reviewing media reports about investigations into certain aspects of the Company's participation in the Medicare program," and is now "complying with formal criminal and civil requests from the Department." The health insurer's stock has been battered by a number of reports this year that authorities are investigating UnitedHealth's Medicare Advantage program. The company has denied claims that it has pressured physicians to bill for certain conditions that could get it larger payouts from the government. The Department of Justice did not immediately respond to a request for comment. UnitedHealth stock also fell this year after its first-quarter results fell short of estimates and the insurer lowered its profit forecast, and after its CEO departed in May. UnitedHealth is scheduled to report earnings before the market opens next Tuesday. The health insurer's stock was down over 3% Thursday afternoon. Shares have lost more than 40% of their value this year, and in May closed at $274.35, their lowest point since early 2020. This article has been updated since it was first published to reflect more recent share price values. Read the original article on Investopedia
